Awardees will receive a $1,500 stipend to cover ACS Fall Meeting expenses. They will present their research at a Women Chemists Committee (WCC)/Merck half-day symposium and be recognized at the Awards ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

Linda Merck works in Seneca, SC as an Addiction and Substance Abuse Counselor. At present, Linda Merck has received an average rating of 1.0 from patients and has been reviewed 1 times.

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall ...

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus ...

Merck broke down the results Friday at the European Society of Medical Oncology Congress in Barcelona. In an email, the company pointed out that the majority of patients in LITESPARK-005 received ...

Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...

“I see these results as important, but preliminary,” Merck Chief Medical Officer Eliav Barr told STAT, reacting to the presentation Sunday of a Phase 3 clinical trial involving ...

Merck & Co.’s best-selling drug Keytruda helped ... The findings, presented Sunday at the European Society for Medical Oncology Congress in Barcelona, show the initial benefits seen with ...

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ...